views
Owing to the numerous benefits
offered by biologics, this drug class has become an integral part of the
overall pharmaceutical industry, having captured a significant market share
over the past couple of decades
Roots
Analysis has announced the addition of the “Top Selling Biologics Market, 2021 – 2030” report to its
list of offerings.
Over the years, around 200 biologics have been approved for
the treatment of various disease indications in the US and Europe. In 2020, 18 new biologics received
approval by the USFDA. Despite their complex and cost intensive manufacturing
protocols, biopharmaceuticals (once approved) are considered to be
highly profitable assets. In the recent past, many biological interventions
have achieved blockbuster status (in some cases, registering revenues worth
over USD 4 billion a year); prominent examples include (arranged in
decreasing order of 2020 revenues) Humira®, Keytruda®, Stelara®, Opdivo®,
Avastin®, Trulicity®, Enbrel®, Ocrevus™ and Rituxan®.
To
order this 320+ page report, which features 190+ figures and 195+ tables,
please visit this https://www.rootsanalysis.com/reports/top-selling-biologics-market.html
Key Market Insights
More than 65 top
selling biologics (revenues equal to or above USD 500 million in 2020)
are currently available in the market
Majority (54%) of the aforementioned candidates are
monoclonal antibodies, followed by hormones (19%) and enzymes (9%). Further, subcutaneous route (50%) emerged as the most
preferred route of administration for such therapies,
followed by the intravenous route (40%).
More than 50% the
developers of top selling biologics are based in North America
The top selling
biologics market is currently dominated by the presence of large companies
(82%). Additionally, majority of such players were established before the year
2000.
Over 2,450 clinical
trials registered for the evaluation of top selling biologics, till Q3 2020
Of the total, 1,892
trials were registered for the evaluation of products targeting oncological
disorders, followed by those investigating biologics intended for the treatment
of metabolic disorders (122) and autoimmune disorders (98).
Around 250
biosimilars of top selling biologics are currently approved / under development
Close to 30% of the
aforementioned candidates have already been approved. It is worth mentioning
that over 100 biosimilars have received approval in Asia Pacific. Within this
region, India and South Korea emerged as key hubs, having granted maximum
approvals for biosimilars of top selling biologics (in terms of 2020
revenues).
Monoclonal antibodies
are anticipated to capture over 75% of the market share by 2030
Over 40% of the
market share is anticipated to be capture by Genentech / Roche and Merck by
2030. It is worth mentioning that as the patents of the currently marketed
products have already / are expected to expire towards the end of the forecast
period, the market is likely to reach maturity.
To request a sample copy / brochure of this
report, please visit this
https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html
Key
Questions Answered
§
Which biologics are likely to attain the blockbuster status
in the foreseen future?
§
Who are the leading players engaged in the development of
top selling biologics?
§
Which key clinical conditions are presently targeted by top
selling biologics?
§
What are the historical global sales of top selling
biologics?
§
Which are the most commonly adopted product life cycle
management strategies by players for their top selling products?
§
What is the current annual treatment cost associated with
top selling biologics?
§
Which regions have emerged as the key hubs for conducting
clinical studies focused on top selling biologics?
§
How has the biosimilars landscape in this market evolved
over the past few years?
§
Which factors are likely to influence the evolution of this
market?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The USD 156 billion (by 2030) financial opportunity
associated with the top selling biologics market has been analyzed across the
following segments:
Type of Biologic
§ Monoclonal
Antibodies
§ Hormones
§ Fusion
Proteins
§ Enzymes
§ Interferons
§ Antibody
Fragments
§ Gene
Therapies
§ Vaccines
Key Developers
§ Genentech
/ Roche
§ AbbVie
§ Janssen
Biotech / Johnson & Johnson
§ Amgen
§ Eli
Lilly
§ Bristol
Myers Squibb
§ Sanofi
§ Novo
Nordisk
§ Regeneron
For
additional details, please visit
https://www.rootsanalysis.com/reports/top-selling-biologics-market.html or email sales@rootsanalysis.com
You
may also be interested in the following titles:
1.
Novel T-Cell Immunotherapies Market, 2021-2030
2.
TIL-based Therapies Market, 2021-2030
3.
Non-Hormonal Therapies Market,
2021-2030
4.
Gene Therapy Market (4th
Edition): Industry Trends and Global Forecasts, 2020-2030
5.
Global T-Cell Therapies Market (5th
Edition): Industry Trends and Global Forecasts, 2021-2030
Contact:
Ben
Johnson
+1
(415) 800 3415
+44
(122) 391 1091